Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione
- Development stage
- Unknown
- Modality
- Small Molecules
01
Overview
This compound is a synthetic small molecule belonging to the bisindolylmaleimide class. It features two indole moieties and a maleimide core with an N-methylpyrrolidine substituent. The molecule is primarily known as bisindolylmaleimide II (BIM 2), an experimental inhibitor of protein kinases, especially protein kinase C (PKC) and cAMP-dependent protein kinase catalytic subunit alpha (PKA). It has been used in biochemical research to study kinase signaling pathways but has not advanced into clinical development or approval for therapeutic use. Its mechanism involves competitive inhibition at the ATP-binding site of target kinases[6][1].
- Other names
- 3-(1H-Indol-3-yl)-4-(1-{2-[(2S)-1-methylpyrrolidin-2-yl]ethyl}-1H-indol-3-yl)-1H-pyrrole-2,5-dioneBIM 2BIM2BIM-2bisindolylmaleimide IICAS RN 137592–45–1
02
Targets
AKT2 (Rac-beta serine/threonine-protein kinase)AKT3 (RAC-gamma serine/threonine-protein kinase)PAK1 (p21-activated kinase 1)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)PKN2 (Protein kinase N2)PRKCD (Protein kinase C delta)SGK3 (Serum/glucocorticoid regulated kinase family member 3)PKA (Cyclic amp-dependent protein kinase)PRKCZ (Protein kinase C zeta)PRKCA (Protein kinase C alpha)RPS6KB1 (Ribosomal protein S6 kinase beta-1)PAK (p21-activated kinase family)SGK1SGK2 (Serum/glucocorticoid regulated kinase 2)TSSK3 (Testis-specific serine/threonine-protein kinase 3)
Beyond the preview
Go deeper on 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 3-(1H-indol-3-yl)-4-{1-[2-(1-methylpyrrolidin-2-yl)ethyl]-1H-indol-3-yl}-1H-pyrrole-2,5-dione.